MA27618A1 - Utilisation des antagonistes du recepteur b2 de la bradykinine pour le traitement de l'osteo-arthrose - Google Patents
Utilisation des antagonistes du recepteur b2 de la bradykinine pour le traitement de l'osteo-arthroseInfo
- Publication number
- MA27618A1 MA27618A1 MA28425A MA28425A MA27618A1 MA 27618 A1 MA27618 A1 MA 27618A1 MA 28425 A MA28425 A MA 28425A MA 28425 A MA28425 A MA 28425A MA 27618 A1 MA27618 A1 MA 27618A1
- Authority
- MA
- Morocco
- Prior art keywords
- bradykinin
- arthrosis
- osteo
- treatment
- diseases
- Prior art date
Links
- 201000008482 osteoarthritis Diseases 0.000 title abstract 3
- 229940123765 Bradykinin B2 receptor antagonist Drugs 0.000 title 1
- 239000003359 bradykinin B2 receptor antagonist Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010003694 Atrophy Diseases 0.000 abstract 1
- 206010060820 Joint injury Diseases 0.000 abstract 1
- 206010065433 Ligament rupture Diseases 0.000 abstract 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000037444 atrophy Effects 0.000 abstract 1
- UYRCOTSOPWOSJK-JXTBTVDRSA-N bradykinin antagonist Chemical compound C1C2=CC=CC=C2CC1[C@@H](NC(=O)C(CO)NC(=O)C(NC(=O)CNC(=O)[C@H]1N(C[C@H](O)C1)C(=O)C1N(CCC1)C(=O)C(CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=N)CCCCCCC(=N)N[C@H](CCCNC(N)=N)C(=O)NC(CCCNC(N)=N)C(=O)N1C(CCC1)C(=O)N1[C@@H](C[C@@H](O)C1)C(=O)NCC(=O)NC(C1CC2=CC=CC=C2C1)C(=O)NC(CO)C(=O)N[C@H](C1CC2=CC=CC=C2C1)C(=O)N1C2CCCCC2CC1C(=O)NC(CCCNC(N)=N)C(O)=O)C1CC2=CC=CC=C2C1)C(=O)N1C2CCCCC2CC1C(=O)NC(CCCNC(=N)N)C(O)=O UYRCOTSOPWOSJK-JXTBTVDRSA-N 0.000 abstract 1
- 239000003152 bradykinin antagonist Substances 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000005499 meniscus Effects 0.000 abstract 1
- 210000004417 patella Anatomy 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 208000005801 spondylosis Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/043—Kallidins; Bradykinins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Les peptides à effet antagoniste de la bradykinine sont adaptés à la préparation de médicaments pour le traitement prophylactique et thérapeutique de maladies dont le développement est en partie dû à l'activité accrue de métalloprotéinases matricielles. Font partie de ces maladies les maladies articulaires dégénératives, par exemple l'ostéoarthrose et la spondylose, l'atrophie du cartilage suite à une lésion articulaire ou à une position de repos prolongée de l'articulation après lésion d'un ménisque ou d'une rotule ou bien des déchirures ligamentaires.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10304994A DE10304994A1 (de) | 2003-02-07 | 2003-02-07 | Die Verwendung von Antagonisten des Bradykinin-B2 Rezeptors zur Behandlung von Osteoarthrose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27618A1 true MA27618A1 (fr) | 2005-11-01 |
Family
ID=32797325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28425A MA27618A1 (fr) | 2003-02-07 | 2005-08-05 | Utilisation des antagonistes du recepteur b2 de la bradykinine pour le traitement de l'osteo-arthrose |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1594520B1 (fr) |
| JP (1) | JP2006516980A (fr) |
| KR (1) | KR20050105447A (fr) |
| CN (1) | CN1317029C (fr) |
| AR (1) | AR043036A1 (fr) |
| AT (1) | ATE335500T1 (fr) |
| AU (1) | AU2004210396A1 (fr) |
| BR (1) | BRPI0407333A (fr) |
| CA (1) | CA2514152C (fr) |
| CO (1) | CO5690613A2 (fr) |
| CY (1) | CY1105708T1 (fr) |
| DE (2) | DE10304994A1 (fr) |
| DK (1) | DK1594520T3 (fr) |
| ES (1) | ES2268622T3 (fr) |
| HR (1) | HRP20050701B1 (fr) |
| IL (1) | IL169899A0 (fr) |
| MA (1) | MA27618A1 (fr) |
| ME (1) | MEP41008A (fr) |
| MX (1) | MXPA05007310A (fr) |
| MY (1) | MY135827A (fr) |
| NO (1) | NO333903B1 (fr) |
| NZ (1) | NZ541680A (fr) |
| PE (1) | PE20040939A1 (fr) |
| PL (1) | PL206412B1 (fr) |
| PT (1) | PT1594520E (fr) |
| RS (1) | RS51029B (fr) |
| RU (1) | RU2329057C2 (fr) |
| TW (1) | TW200505472A (fr) |
| WO (1) | WO2004069266A2 (fr) |
| ZA (1) | ZA200505177B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0710522D0 (en) * | 2007-06-01 | 2007-07-11 | Royal Veterinary College The | Drug delivery system comprising matrix metalloproteinase inhibitors |
| IT1391236B1 (it) | 2008-07-11 | 2011-12-01 | St Luso Farm D'italia Spa | Composizioni farmaceutiche a base di antagonisti del recettore b2 delle chinine e corticosteroidi e loro uso |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE63490B1 (en) * | 1988-11-24 | 1995-05-03 | Hoechst Ag | Peptides having bradykinin antagonist action |
| MX9100717A (es) * | 1990-08-24 | 1992-04-01 | Syntex Inc | Antagonistas de la bradiquinina |
| FR2751650B1 (fr) * | 1996-07-24 | 1998-10-09 | Fournier Ind & Sante | Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique |
| FR2751878B1 (fr) * | 1996-07-30 | 1998-09-04 | Oreal | Utilisation dans une composition d'un extrait d'au moins une labiee |
| US6346519B1 (en) * | 1998-09-09 | 2002-02-12 | Advanced Medical Instruments | Method and composition for treating arthritis |
| CA2364178C (fr) * | 2000-12-05 | 2006-01-10 | Yasuhiro Katsu | N-benzenesulfonyl-l-prolines utilisees comme antagonistes de la bradykinine |
| JP2005519917A (ja) * | 2002-02-01 | 2005-07-07 | オメロス コーポレイション | 軟骨分解の全身阻害のための組成物および方法 |
-
2003
- 2003-02-07 DE DE10304994A patent/DE10304994A1/de not_active Withdrawn
-
2004
- 2004-01-13 PE PE2004000064A patent/PE20040939A1/es not_active Application Discontinuation
- 2004-01-23 PT PT04704552T patent/PT1594520E/pt unknown
- 2004-01-23 ME MEP-410/08A patent/MEP41008A/xx unknown
- 2004-01-23 CN CNB2004800034498A patent/CN1317029C/zh not_active Expired - Fee Related
- 2004-01-23 PL PL376605A patent/PL206412B1/pl unknown
- 2004-01-23 KR KR1020057014116A patent/KR20050105447A/ko not_active Ceased
- 2004-01-23 EP EP04704552A patent/EP1594520B1/fr not_active Expired - Lifetime
- 2004-01-23 RU RU2005127862/15A patent/RU2329057C2/ru not_active IP Right Cessation
- 2004-01-23 DE DE502004001159T patent/DE502004001159D1/de not_active Expired - Lifetime
- 2004-01-23 AT AT04704552T patent/ATE335500T1/de active
- 2004-01-23 BR BR0407333-9A patent/BRPI0407333A/pt not_active IP Right Cessation
- 2004-01-23 RS YUP-2005/0565A patent/RS51029B/sr unknown
- 2004-01-23 ES ES04704552T patent/ES2268622T3/es not_active Expired - Lifetime
- 2004-01-23 JP JP2006501585A patent/JP2006516980A/ja active Pending
- 2004-01-23 HR HRP20050701AA patent/HRP20050701B1/hr not_active IP Right Cessation
- 2004-01-23 MX MXPA05007310A patent/MXPA05007310A/es active IP Right Grant
- 2004-01-23 WO PCT/EP2004/000550 patent/WO2004069266A2/fr not_active Ceased
- 2004-01-23 CA CA2514152A patent/CA2514152C/fr not_active Expired - Fee Related
- 2004-01-23 NZ NZ541680A patent/NZ541680A/en not_active IP Right Cessation
- 2004-01-23 AU AU2004210396A patent/AU2004210396A1/en not_active Abandoned
- 2004-01-23 DK DK04704552T patent/DK1594520T3/da active
- 2004-02-05 TW TW093102562A patent/TW200505472A/zh unknown
- 2004-02-05 AR ARP040100363A patent/AR043036A1/es unknown
- 2004-02-06 MY MYPI20040362A patent/MY135827A/en unknown
-
2005
- 2005-06-27 ZA ZA200505177A patent/ZA200505177B/en unknown
- 2005-07-26 IL IL169899A patent/IL169899A0/en unknown
- 2005-08-03 CO CO05076615A patent/CO5690613A2/es not_active Application Discontinuation
- 2005-08-05 MA MA28425A patent/MA27618A1/fr unknown
- 2005-09-06 NO NO20054144A patent/NO333903B1/no not_active IP Right Cessation
-
2006
- 2006-10-16 CY CY20061101482T patent/CY1105708T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0010138A (pt) | Moduladores de receptores de glucocorticóides | |
| AR035828A1 (es) | Abridor de canal k activado por calcio de gran conductancia, uso del mismo o de un compuesto de azol sustituido para preparar un medicamento, compuesto de azol sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento | |
| BR9915943A (pt) | Formulação de liberação controlada compreendendo gnrh-ii | |
| IL132661A0 (en) | Agonists specific for the peripheral cannabinoid receptor | |
| EP2037739A4 (fr) | Effecteurs allostériques positifs du récepteur m1 à base de quinolone à substitution benzyle | |
| BR0309969A (pt) | Uso de compostos que são eficazes como moduladores de receptores seletivos de opiáceos | |
| DE60042496D1 (de) | Verwendung von retinoid rezeptor antagonisten für die behandlung von knochen und knorpel pathologien | |
| BR0209662A (pt) | Método para o tratamento e/ou profilaxia de condições caracterizadas pela função alterada de instestino e/ou dor visceral em seres humanos ou mamìferos não humanos | |
| FR06C0032I2 (fr) | Formulations proteiniques | |
| BR9813208A (pt) | Antagonista receptor de vitronectina | |
| BR0209290A (pt) | Tratamento de demência e doenças neurodegenerativas com doses intermediárias de antagonistas de lhrh | |
| MX2007004199A (es) | Derivados de indol sustituidos con 5-sulfonil-1-piperidinil como antagonistas del receptor 5-ht6 para el tratamiento de trastornos del cns. | |
| BR0015172A (pt) | Nova combinação compreendendo um agonista adreno receptor de beta 2 (beta 2) e um antagonista receptor de leucotrieno | |
| KR970706827A (ko) | 필요시 투여되는 여성 산아 조절용 경쟁 프로게스테론 길항제 | |
| PA8600101A1 (es) | Derivados de 3-azabiciclo[3.2.1]octano | |
| BR0307504A (pt) | Composto ou sal farmaceuticamente aceitável, composição farmacêutica, métodos tratar doenças, para potencializar um efeito terapêutico de um agente para o snc, para melhorar a memória de curto prazo em um paciente, para determinar a presença ou ausência de receptores gabaa em uma amostra, e para alterar a atividade transdutora de sinal do receptor gabaa, embalagem, e, uso de um composto ou sal | |
| BRPI0408956A (pt) | emprego de derivativos de carbamazepina para o tratamento de agitação em pacientes com demência | |
| BR0211498A (pt) | Uso de antagonistas de lhrh em doses que não causam castração, para a melhora de imunidade mediada por células t | |
| Schott | The idiopathic dystonias. A note on their orthopaedic presentation | |
| BR0308517A (pt) | Combinação de um antagonista do receptor de aldosterona e de um agente sequestrante de ácido biliar | |
| BR0009327A (pt) | Composição farmacêutica para a terapia de sintomas do trato urinário inferior | |
| IL153058A0 (en) | Agents and methods for increasing brain chaperonin levels | |
| TW200505472A (en) | The use of antagonists of the bradykinin b2 receptor for the treatment of osteoarthrosis | |
| Grobler | Unusual cause of ulnar nerve palsy. | |
| ZA962176B (en) | Use of antioestrogens for controlling male fertility |